He Huang, MD
First Affiliated Hospital of Zhejiang University
15
15
1
N/A
0
2
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+7 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (15)
Showing 10 of 15 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Xi Zhang, MD phD
Xinqiao Hospital of Chongqing
Shared therapeutic areas:
Worked with same sponsors:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Richard W Childs, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Shared therapeutic areas:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Courtney DiNardo, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Jorge E Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Arnon Nagler, MD
Chaim Sheba Medical Center
Shared therapeutic areas:
Yves Beguin, MD, PhD
CHU-ULg
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (15)
Showing 15 of 15 trials
KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT
Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML
AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma
Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia
Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia
All 15 trials loaded